Dr. Klaus Schollmeier

Biography

More than 25 years of successful international management experience in the pharmaceutical and biotech industry as well as in investment banking. From 2013-2015 Chief Executive Officer of SuppreMol GmbH in Munich, Germany. In 2015 SuppreMol was acquired by Baxter in a € 220 Mio. deal. Before that he led Santhera Pharmaceuticals AG as CEO since the company’s foundation in 2004, took the company public in 2006 and launched the first product in 2008. Before that he spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott. His scientific responsibilities included head of oncology/immunology research at BASF’s central laboratories in Germany, and senior director of biotechnology at BASF Bioresearch Corporation in Cambridge, US. His business functions included General Manager of BASF Pharma Netherlands and Vice President and General Manager for Western Europe Today, Klaus is CEO of KCS-GmbH, a consulting and investment company and he serves as non-executive chairman of several European Biotechnology companies Klaus holds a Ph.D. in Biology from the University of Düsseldorf, Germany.

Research Interest

biotechnology